GLP-1s for men: muscle preservation is the whole game.

Without a protocol, roughly a third of the weight a man loses on semaglutide or tirzepatide is lean mass. For a 50-year-old man, that is worse than the obesity it is treating.

The dominant narrative around GLP-1 agonists is "the weight comes off." True. The narrative most men over 40 are not hearing clearly is which weight comes off, and why for a midlife man that matters more than the headline number on the scale.

In the major trials, roughly 30 to 40 percent of total weight lost on GLP-1 therapy is lean mass, not fat. For a young woman, that fraction is recoverable. For a 50-year-old man already on the downslope of the sarcopenia curve, with declining testosterone and bone density, an uncontrolled GLP-1 cut can age him by ten years. The drug is not the problem. The protocol is.

What the trials actually show

STEP-1, the landmark semaglutide trial published by Wilding and colleagues in the New England Journal of Medicine in 2021, randomized 1,961 adults with overweight or obesity to weekly 2.4 mg semaglutide or placebo. At 68 weeks, the semaglutide group had lost a mean of 14.9 percent of body weight versus 2.4 percent on placebo.

SURMOUNT-1, the tirzepatide trial published by Jastreboff and colleagues in 2022, hit harder. At 72 weeks the highest dose produced a mean weight loss of 20.9 percent, the largest pharmaceutical weight loss recorded in a Phase 3 trial.

What the headlines do not show is the body composition substudy. In the STEP-1 DEXA substudy, of total weight lost on semaglutide, roughly 39 percent was lean mass. SURMOUNT-1 body composition tracked a similar pattern. A more powerful drug without a counter-protocol produces a more powerful muscle loss.

The STEP-4 trial tested the other end of the curve. Patients who stopped semaglutide regained roughly two-thirds of the lost weight within a year, body composition recomposing toward baseline. The drug is a tool, not an event.

Why this is worse for men than for women

Men over 40 are already losing muscle. The sarcopenia curve starts gently in the third decade and steepens through midlife: roughly 0.5 to 1 percent loss of skeletal muscle per year after 50. Testosterone, the primary anabolic signal in male muscle, is also declining (1 to 2 percent per year after 30). Bone density follows the same arc.

A 50-year-old man starting a GLP-1 without a resistance training and protein protocol is layering an acute lean-mass loss on top of a chronic one. The headline 15 percent weight loss feels great in the mirror at week 30, but the underlying picture — less muscle, lower testosterone, weaker bone, a reset metabolic floor — is a man who has aged metabolically by a decade in eight months.

This is the part the prescriber rarely discusses, in part because the prescriber is a telehealth doctor optimizing for adherence, not for the muscle of a 50-year-old over the next twenty years.

The protocol that actually preserves muscle

The Stiegler and Cunliffe 2006 paper in Sports Medicine remains one of the cleanest reviews of how to preserve fat-free mass during caloric restriction. The interventions that work are the boring ones, applied together: progressive resistance training, sufficient protein, adequate energy availability on training days, and a rate of loss slow enough to permit muscle protein synthesis.

Translated to a GLP-1 protocol for a midlife man, the components are these.

Resistance training, three to four sessions per week. Not cardio. Compound lifts — squat, deadlift, press, row, pull — with progressive load. The training is the signal that says "do not catabolize this muscle." Two sessions is the floor. Four is better.

Protein at 1.6 g/kg body weight per day. This is the upper end of the meta-analytic evidence for muscle preservation during a cut, and non-negotiable on a GLP-1. The drugs blunt appetite globally, so men accidentally eat 0.6 g/kg of protein on autopilot. That is the level at which lean mass loss accelerates. Track it.

Creatine monohydrate, 5 g per day. The most-studied performance supplement, with consistent evidence for strength and muscle preservation in older adults. Cheap, safe, and one of the few supplements that actually shifts the outcome.

Vitamin D, omega-3, and adequate sleep. Each has independent evidence for muscle protein synthesis and recovery. None is glamorous. All load-bearing.

Bloodwork every 12 weeks. Total and free testosterone, SHBG, IGF-1, lipid panel, fasting glucose and HbA1c, CBC, comprehensive metabolic panel. The point is to confirm the GLP-1 is doing what the trials promised without collapsing testosterone or stressing kidneys.

When to taper, when to cycle

The hardest part of the GLP-1 conversation is what comes after. The drugs are not curative. Stopping abruptly produces a rebound, the metabolic adaptation of the cut is still in place, and most patients regain a meaningful fraction of the weight within a year.

The honest framing is that GLP-1s are likely a long-term medication for most patients who respond, similar to statins or blood pressure drugs. For some, that is the right answer. For others, the better play is the drug as a structured tool: 6 to 12 months on with an aggressive muscle-preservation protocol, then a slow taper, with lifestyle changes locked in.

The taper should be gradual — typically halving the dose every 4 to 6 weeks — and combined with deliberate protein and training reinforcement to prevent rebound. Some patients cycle. There is not yet a definitive trial. The principle that holds is that muscle is harder to build than lose, so the protocol must protect it on the drug and during the transition off.

Who should not start a GLP-1

A short list. Men with personal or family history of medullary thyroid cancer or MEN2. Men with a history of pancreatitis. Men who will not commit to the training and protein protocol — for them the drug produces sarcopenic obesity, worse than where they started. Men whose underlying issue is poor sleep or untreated depression, where the GLP-1 masks but does not address the upstream cause.

The bottom line

The GLP-1 era is the most significant pharmacological event in metabolic medicine in a generation. For the right midlife man, the drugs do what the trials say — meaningful weight loss, better cardiometabolic markers, reduced visceral adiposity.

For the wrong midlife man, or the right one on a bad protocol, the same drugs accelerate sarcopenia, depress testosterone, and produce a thinner, weaker, more fragile version of the body he came in with. The drug is the same. The protocol is the variable. For a man over 40, the protocol is not optional, it is the whole game.